This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 20, 2016 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: Starting Year 20! |
Vol. 20 No. 1 |
4 |
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis |
Vol. 20 No. 1 |
6 |
Microbial Identification in Pharmaceutical Compounding |
Vol. 20 No. 1 |
13 |
Basic Principles of Lyophilization, Part 2 |
Vol. 20 No. 1 |
20 |
Performance Improvement in 503A Compounding Pharmacies: A Plan for Assessment, Implementation, and Sustained Success |
Vol. 20 No. 1 |
29 |
Formulation and Stability of Solutions |
Vol. 20 No. 1 |
41 |
Calculations |
Vol. 20 No. 1 |
46 |
Aprepitant 80-mg Capsules |
Vol. 20 No. 1 |
48 |
Aripiprazole 10-mg Oral Dissolving Tablets |
Vol. 20 No. 1 |
49 |
Benzocaine 20%, Lidocaine 6%, and Tetracaine 4% in Lipoderm |
Vol. 20 No. 1 |
50 |
Dexamethasone, Neomycin, and Polymyxin Ophthalmic Ointment |
Vol. 20 No. 1 |
51 |
Mupirocin Calcium 2% Cream |
Vol. 20 No. 1 |
52 |
Resveratrol, Tocopherol Acetate, and Niacinamide Topical Gel-Cream |
Vol. 20 No. 1 |
53 |
Thrombin 1,000 Units/mL Topical Solution, Sterile |
Vol. 20 No. 1 |
54 |
Tropicamide 1% Ophthalmic Solution |
Vol. 20 No. 1 |
55 |
Vancomycin 5% and Amikacin 2% Ophthalmic Solution |
Vol. 20 No. 1 |
56 |
Voriconazole 10-mg/mL Ophthalmic Solution |
Vol. 20 No. 1 |
57 |
Antimicrobial Activity of Copaiba (Copaifera officinalis) and Pracaxi (Pentaclethra macroloba) Oils against Staphylococcus aureus: Importance in Compounding for Wound Care |
Vol. 20 No. 1 |
58 |
Validation of Ultraviolet-visible and High-performance Liquid Chromatographic Methods for the Determination of Sodium p-Aminosalicylate and m-Aminophenol in a New Pharmaceutical Formulation |
Vol. 20 No. 1 |
63 |
A Novel Vehicle for Enhanced Drug Delivery Across the Human Nail for the Treatment of Onychomycosis |
Vol. 20 No. 1 |
71 |
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date |
Vol. 20 No. 1 |
81 |
PostScription: The Home Field Advantage |
Vol. 20 No. 1 |
86 |
PreScription: Compounding: A Changing Paradigm |
Vol. 20 No. 2 |
92 |
Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations |
Vol. 20 No. 2 |
95 |
Root Cause Analysis, Part 2: Sterile Compounding |
Vol. 20 No. 2 |
99 |
Topical Ketamine: A Review of the History, Mechanisms, Uses, Safety, and Future |
Vol. 20 No. 2 |
107 |
Pharmaceutical Compounding in Portuguese Community Pharmacies: Characterization and Future Perspectives |
Vol. 20 No. 2 |
114 |
Basics of Compounding: Capsules |
Vol. 20 No. 2 |
125 |
Formulation and Stability of Solutions |
Vol. 20 No. 2 |
137 |
Calculations |
Vol. 20 No. 2 |
142 |
Blue Goo Anti-Itch Gel |
Vol. 20 No. 2 |
144 |
Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules |
Vol. 20 No. 2 |
145 |
Medicated Polyox Bandage for Skin Ulcers |
Vol. 20 No. 2 |
146 |
Sumatriptan 5-mg or 20-mg per 100-μL Nasal Spray |
Vol. 20 No. 2 |
147 |
Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal) |
Vol. 20 No. 2 |
148 |
Utilization of Compounded Medications in an Oral Medicine Practice |
Vol. 20 No. 2 |
155 |
Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups |
Vol. 20 No. 2 |
159 |
Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures |
Vol. 20 No. 2 |
164 |
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions |
Vol. 20 No. 2 |
167 |
PreScription: Patient Access to Pharmaceuticals |
Vol. 20 No. 3 |
180 |
Current Perspectives on the Syringe Delivery System |
Vol. 20 No. 3 |
182 |
Compounding in Nigeria |
Vol. 20 No. 3 |
189 |
IACP Names Voliva Executive Vice President |
Vol. 20 No. 3 |
194 |
Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients |
Vol. 20 No. 3 |
197 |
Does Your Drug Expertise Include Clinical Pharmaceutics? |
Vol. 20 No. 3 |
202 |
Basics of Compounding: Special Capsules |
Vol. 20 No. 3 |
209 |
Basics of Sterile Compounding: Clinical Hazards of Injectable Drug Administration |
Vol. 20 No. 3 |
217 |
Calculations |
Vol. 20 No. 3 |
224 |
Carboplatin 50-mg/mL Injection |
Vol. 20 No. 3 |
226 |
Cefotetan Disodium Injection |
Vol. 20 No. 3 |
227 |
Dexamethasone 0.1%, Neomycin 0.35%, and Polymixin 10,000 Units/g Ophthalmic Ointment |
Vol. 20 No. 3 |
228 |
Dexpanthenol 5% Nasal Spray |
Vol. 20 No. 3 |
229 |
Indomethacin Gel |
Vol. 20 No. 3 |
230 |
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm |
Vol. 20 No. 3 |
231 |
Montelukast Sodium 5-mg Fast-Dissolving Film |
Vol. 20 No. 3 |
232 |
Pain-Away II Headache Capsules |
Vol. 20 No. 3 |
233 |
Sodium Nitroprusside 25-mg/mL Injection |
Vol. 20 No. 3 |
234 |
Zolpidem Tartrate 5-mg and 10-mg Capsules |
Vol. 20 No. 3 |
235 |
Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration |
Vol. 20 No. 3 |
236 |
Topical Metered-dosing Dispenser Performance Evaluation |
Vol. 20 No. 3 |
239 |
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children |
Vol. 20 No. 3 |
247 |
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives |
Vol. 20 No. 3 |
250 |
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children |
Vol. 20 No. 3 |
257 |
PostScription: Supporting Your Alma Mater: Whose World Will You Change? |
Vol. 20 No. 3 |
262 |
PreScription: Is the United States Pharmacopeial Convention, Inc., Authorized to Establish "Official" Practice Standards for Pharmacy, Medicine, and Nursing? |
Vol. 20 No. 4 |
268 |
Compounding Transdermal Medication for Feline Patients |
Vol. 20 No. 4 |
271 |
Case Report: Pediatric Scar Management After Open-heart Surgery |
Vol. 20 No. 4 |
277 |
Choosing a Vial Processing Line for Aseptic Compounding: Part 1 |
Vol. 20 No. 4 |
283 |
IACP's 2016 Compounders on Capitol Hill Asks |
Vol. 20 No. 4 |
294 |
Basics of Compounding: Compounding Films |
Vol. 20 No. 4 |
298 |
Basics of Sterile Compounding: Personnel Requirements for Sterile Compounding |
Vol. 20 No. 4 |
307 |
Calculations |
Vol. 20 No. 4 |
316 |
Dolasetron Mesylate 20-mg/mL Injection |
Vol. 20 No. 4 |
318 |
Gatifloxacin 0.5% Ophthalmic Solution |
Vol. 20 No. 4 |
319 |
Mebendazole 100-mg Capsules |
Vol. 20 No. 4 |
320 |
Neomycin Sulfate 25-mg/mL Oral Solution |
Vol. 20 No. 4 |
321 |
Nystatin 100,000-units Vaginal Inserts |
Vol. 20 No. 4 |
322 |
1,2-Octanediol 5% Topical Liquid |
Vol. 20 No. 4 |
323 |
Phytonadione 1-mg/mL Oral Solution |
Vol. 20 No. 4 |
324 |
Plasmingen and Hyaluronate Sodium Ophthalmic Solution |
Vol. 20 No. 4 |
325 |
Scopolamine Hydrobromide 0.25% Ophthalmic Solution |
Vol. 20 No. 4 |
326 |
Tretinoin 10-mg Oral Capsules |
Vol. 20 No. 4 |
327 |
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures |
Vol. 20 No. 4 |
328 |
Evaluation of the Antibacterial Activity of Green Propolis Extract and Meadowsweet Extract Against Staphylococcus aureus Bacteria: Importance in Would Care Compounding Preparations |
Vol. 20 No. 4 |
333 |
Stability of Ampicillin in Normal Saline and Buffered Normal Saline |
Vol. 20 No. 4 |
338 |
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump |
Vol. 20 No. 4 |
343 |
Long-term Stability of Vancomycin Hydrochloride in Oral Solution: The Brand Name Versus a Generic Product |
Vol. 20 No. 4 |
347 |
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines |
Vol. 20 No. 4 |
351 |
PreScription: Stability Studies and United States Pharmacopeia-National Formulary-Grade Chemicals |
Vol. 20 No. 5 |
356 |
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 |
Vol. 20 No. 5 |
359 |
Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy |
Vol. 20 No. 5 |
367 |
More than 300 Attendees Convene in Washington, DC, for the 22nd Annual Compounders on Capitol Hill: The United Voice of Compounders is Heard! |
Vol. 20 No. 5 |
377 |
Quality Control Analytical Methods: Method Validation |
Vol. 20 No. 5 |
381 |
Basics of Compounding: Clinical Pharmaceutics, Part 1 |
Vol. 20 No. 5 |
389 |
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions |
Vol. 20 No. 5 |
399 |
Calculations |
Vol. 20 No. 5 |
405 |
Clobazam 1-mg/mL Oral Suspension |
Vol. 20 No. 5 |
406 |
Estradiol 0.25 mg/g, Estrone 0.25 mg/g, and Estriol 2 mg/g in HRT Cream Base |
Vol. 20 No. 5 |
407 |
Inamrinone 5-mg/mL Injection |
Vol. 20 No. 5 |
408 |
Levetiracetam 50-mg/mL Oral Suspension |
Vol. 20 No. 5 |
409 |
Naproxen 5% Cream |
Vol. 20 No. 5 |
410 |
Permethrin 1% Lotion |
Vol. 20 No. 5 |
411 |
Progesterone 10% Cream |
Vol. 20 No. 5 |
412 |
Sodium Phosphate Oral Solution |
Vol. 20 No. 5 |
413 |
Tetracaine Hydrochloride 2% Topical Solution |
Vol. 20 No. 5 |
414 |
Tromethamine Injection |
Vol. 20 No. 5 |
415 |
Long-term Stability of Vancomycin Hydrochloride in Glucose 5% Polyolefin Bags: The Brand Name Versus a Generic Product |
Vol. 20 No. 5 |
416 |
Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt |
Vol. 20 No. 5 |
421 |
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions |
Vol. 20 No. 5 |
426 |
Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light |
Vol. 20 No. 5 |
435 |
A Simplified Extemporaneously Prepared Potassium Chloride Oral Solution |
Vol. 20 No. 5 |
438 |
PreScription: Two Decades of IJPC |
Vol. 20 No. 6 |
444 |
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 |
Vol. 20 No. 6 |
447 |
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) |
Vol. 20 No. 6 |
457 |
Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy |
Vol. 20 No. 6 |
461 |
Why Become Pharmacy Compounding Accreditation Board Accredited? |
Vol. 20 No. 6 |
469 |
The "Lists": What Do They Mean? |
Vol. 20 No. 6 |
477 |
Introduction to Quality Control in a Compounding Pharmacy |
Vol. 20 No. 6 |
481 |
Basics of Compounding: Clinical Pharmaceutics, Part 2 |
Vol. 20 No. 6 |
485 |
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments |
Vol. 20 No. 6 |
495 |
Calculations |
Vol. 20 No. 6 |
502 |
Alendronate 70-mg/75-mL Drinkable Formulation |
Vol. 20 No. 6 |
504 |
Bosentan 6.25-mg/mL Oral Suspension |
Vol. 20 No. 6 |
505 |
Capsaicin 0.025% and Doxepin 3.3% Cream |
Vol. 20 No. 6 |
506 |
Enrofloxacin 0.5%, Ketoconazole 0.1%, and Triamcinolone Acetonide 0.1% Otic Gel |
Vol. 20 No. 6 |
507 |
Erlotinib 10-mg/mL Oral Suspension |
Vol. 20 No. 6 |
508 |
Flumazenil 0.1-mg/mL Injection |
Vol. 20 No. 6 |
509 |
Imatinib 40-mg/mL Oral Suspension |
Vol. 20 No. 6 |
510 |
Lapatinib Ditosylate 50-mg/mL Oral Suspension |
Vol. 20 No. 6 |
511 |
Melatonin 2-mg/mL Oral Suspension |
Vol. 20 No. 6 |
512 |
Menthol, Chloral Hydrate, and Camphor Analgesic Ointment |
Vol. 20 No. 6 |
513 |
Stability of Fentanyl Citrate in Polyolefin Bags |
Vol. 20 No. 6 |
514 |
Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial |
Vol. 20 No. 6 |
517 |
Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature |
Vol. 20 No. 6 |
521 |
PostScription: What Lies Beneath: Potentially Harmful Excipients to Avoid when Compounding for Small Animals--A Note of Caution |
Vol. 20 No. 6 |
526 |